Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02289417 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT02289417 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 170 participants.
The verdict
NCT02289417, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of apremilast (30 mg twice daily \[BID\] and 40 mg BID), compared with placebo, in participants with active Ulcerative Colitis (UC).
Interventions
- DRUG Placebo
- DRUG Apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2015-01-08 |
| Est. Completion | 2019-06-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02289417
The ClinicalTrials.gov registry entry for NCT02289417 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02289417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02289417 about?
NCT02289417 is a clinical study titled "Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis". The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of apremilast (30 mg twice daily \[BID\] and 40 mg BID), compared with placebo, in participants with active Ulcerative Colitis (UC).
What is the current status of trial NCT02289417?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2015-01-08. Estimated completion is 2019-06-03.
What interventions are being tested in trial NCT02289417?
The interventions under investigation include: Placebo (DRUG), Apremilast (DRUG).
Who is sponsoring clinical trial NCT02289417?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.